cabergoline has been researched along with Adverse Drug Event in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (28.57) | 29.6817 |
| 2010's | 3 (42.86) | 24.3611 |
| 2020's | 2 (28.57) | 2.80 |
| Authors | Studies |
|---|---|
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Ding, D; Fang, H; Kelly, R; Liu, Z; Shi, Q; Tong, W | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Huang, Q; Li, M; Tan, J; Zeng, Y; Zhou, W; Zou, Y | 1 |
| Albarel, F; Amodru, V; Brue, T; Castinetti, F; Cuny, T; Dufour, H; Graillon, T; Morange, I | 1 |
| Auriemma, RS; Colao, A; Grasso, LF; Pivonello, R | 1 |
| Chung, TT; Drake, WM; Higham, CE; Lawrance, J; Trainer, PJ | 1 |
3 review(s) available for cabergoline and Adverse Drug Event
| Article | Year |
|---|---|
The efficacy and safety of quinagolide in hyperprolactinemia treatment: A systematic review and meta-analysis.
Topics: Aminoquinolines; Bromocriptine; Cabergoline; Drug-Related Side Effects and Adverse Reactions; Humans; Hyperprolactinemia; Pituitary Neoplasms | 2023 |
The risks of medical treatment of prolactinoma.
Topics: Cabergoline; Dopamine Agonists; Drug-Related Side Effects and Adverse Reactions; Fibrosis; Heart Valve Diseases; Humans; Neurosurgical Procedures; Pituitary Neoplasms; Prolactinoma; Substance-Related Disorders | 2021 |
The safety of treatments for prolactinomas.
Topics: Animals; Antineoplastic Agents; Cabergoline; Dopamine Agonists; Drug-Related Side Effects and Adverse Reactions; Ergolines; Humans; Pituitary Neoplasms; Prolactinoma; Safety | 2016 |
1 trial(s) available for cabergoline and Adverse Drug Event
| Article | Year |
|---|---|
Long-term experience of pegvisomant therapy as a treatment for acromegaly.
Topics: Acromegaly; Adult; Aged; Cabergoline; Drug-Related Side Effects and Adverse Reactions; Ergolines; Female; Human Growth Hormone; Humans; Insulin-Like Growth Factor I; Male; Middle Aged; Retrospective Studies; Somatostatin; Treatment Outcome | 2009 |
3 other study(ies) available for cabergoline and Adverse Drug Event
| Article | Year |
|---|---|
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
Topics: Animals; Anti-Infective Agents; Anti-Inflammatory Agents; Chemical and Drug Induced Liver Injury; Databases, Factual; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Models, Biological; Predictive Value of Tests | 2011 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |